City
Epaper

Dr Ajit Kamath, Managing Director, Ms Arch Pharmalabs Ltd conferred Honorary Doctorate in Health Administration

By ANI | Updated: February 4, 2022 14:50 IST

Dr Ajit Kamath, Promoter and Managing Director of Ms Arch Pharmalabs Ltd, was conferred "Honorary Doctorate in Health Administration" by prestigious university The Indian Institute of Technical Research and Business Studies for his exemplary contribution of over 25 years in the field of Pharmaceuticals in a virtual ceremony commemorating 73 Years of the Republic of India.

Open in App

Dr Ajit Kamath, Promoter and Managing Director of Ms Arch Pharmalabs Ltd, was conferred "Honorary Doctorate in Health Administration" by prestigious university The Indian Institute of Technical Research and Business Studies for his exemplary contribution of over 25 years in the field of Pharmaceuticals in a virtual ceremony commemorating 73 Years of the Republic of India.

Headquartered in Mumbai, Arch Pharmalabs Ltd. is a pharmaceutical company based out of India. With its products verticle, Arch Pharmalabs facilitates the production and distribution of Active Pharmaceutical Ingredients (APIs) and intermediates to international and national generic pharmaceutical players and innovators.

Arch has multiple USFDA approved facilities with multiple chemistry capabilities from kilogram to multi-ton scale. Arch has been at the forefront of attracting and practicing path-breaking technologies in the field of manufacturing APIs and Intermediates. Arch has been commercially manufacturing various import substitutes and complex intermediates covering, but not limited to, blockbuster drugs like Atorvastatin, Rosuvastatin, Ursodeoxycholic Acid, etc. Recently it has also diversified into Lithium compounds.

For over two and a half decades, Dr Ajit Kamath has had extensive top-level decision-making and risk-taking experience in Arch Pharmalabs Limited's dynamic global business.

Accepting the degree, Dr Ajit Kamath said, "I am extremely honored to receive this Honorary Doctorate from a University that plays such an important role in developing the potential and talent of tens of thousands of students from all over the world. May you all be fortunate enough to know someone who will inspire you to feel the joy and satisfaction that comes from helping others."

The pharmaceutical company is dedicated to achieving complete customer satisfaction through its advanced quality management system and compliance with all regulatory requirements. They ensure compliance with cGMP, ICH Q7A, ISO, pharmacopoeial requirements, and other industry standards to win customer confidence. Under Dr Ajit's leadership, the company is looking forward to continuing to offer unique and innovative solutions to the global pharma industry.

To know more visit-

This story is provided by TPT.will not be responsible in any way for the content of this article. (ANI/TPT)

( With inputs from ANI )

Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor

Tags: mumbaiRepublic of indiaMs arch pharmalabs ltdIndian institute of technical research and business studiesAjit kamath
Open in App

Related Stories

ThaneThane Traffic Update: Ghodbunder Road Repairs to Disrupt Vehicular Movement From April 26 To 29

National‘Question Kunal Kamra In Chennai’: Bombay HC To Police; Grants Protection From Arrest

MumbaiMumbai 1 App Likely To Launch On May 1

ThaneThane: Fire Breaks Out in Scrap Warehouse in Bhiwandi, Damage Estimated in Millions (Watch Video)

MumbaiMumbai on High Alert, Security Tightened at Public Places After Pahalgam Terror Attack

Business Realted Stories

BusinessEmployment in India grown faster than working-age population: World Bank report

BusinessCentre to unveil digital portal for medical value travel: Minister

BusinessIndiGo flight schedule hit as Pakistan shuts airspace

BusinessReliance posts record revenues in FY25, becomes first Indian company to cross Rs 10 lakh crore in total equity

BusinessIndia's direct tax collections surge 15.6% to Rs 27 lakh crore in 2024-25